HSBC raised the firm’s price target on Bristol Myers (BMY) to $60 from $53 and keeps a Hold rating on the shares. The firm says the uncertain macro backdrop, rising geopolitical risk, and lower exposure to AI disruption risks could attract investors to healthcare and drive outperformance in the coming quarter.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- District court rules federal limits to vaccines not based on science, NYT says
- BMY Targets Real-World Edge for Ozanimod in Ulcerative Colitis
- Colgate-Palmolive names Bristol-Myers CEO Boerner to board
- Curanex appoints two research experts to board of directors
- Balanced Outlook on BMY: Positive Mezigdomide Phase III Data Support CELMoD Platform, but Long-Term Execution Risks Warrant Hold Rating